Amifostine and chemoradiation therapy: ASCO responds

Lancet Oncology

Volumn 4, Issue 10, 2003, Pages 593-

  Schuchter, Lynn ^a   Meropol, Neal J ^b   Winer, Eric P ^c   Hensley, Martee L ^d   Somerfield, Mark R ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG USE; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NOTE; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; XEROSTOMIA;

EID: 0141963142     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01216-6     Document Type: Letter

References (3)

1. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003; 4: 378-81.
2. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-55.
3. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-903.